102
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

The Emergence of Novel Spoligotypes of Highly Drug-Resistant Mycobacterium tuberculosis Isolates in Fujian, China

, ORCID Icon, , , & ORCID Icon
Pages 5781-5793 | Received 02 Jul 2022, Accepted 11 Sep 2022, Published online: 01 Oct 2022
 

Abstract

Background

Here, we aimed to determine the population structure of Mycobacterium tuberculosis (MTB) genotypes in Fujian and explore risk factors associated with infection with the Beijing genotype. We also explored the association between Beijing genotype and drug resistance.

Methods

Representative MTB isolates obtained during provincial-level routine anti-tuberculosis drug resistance surveillance conducted since 2013 in 11 Fujian counties were analyzed using McSpoligotyping. In vitro drug susceptibilities to anti-tuberculosis drugs were determined using the standard Löwenstein–Jensen proportion method.

Results

Overall, 477 MTB isolates were included in the study, of which 245 isolates belonged to the Beijing genotype family and 232 possessed non-Beijing genotypes. Ultimately, a total of 204 spoligotypes were identified that included 58 spoligotype international types (SITs) from the SITVITWEB database and 146 novel spoligotypes. As compared to patients <25 years of age (control group), elderly patients (≥65 years of age) were more likely to be infected with non-Beijing genotypes [aOR 18.69, 95% CI (5.80–60.26)], with risk of infection with non-Beijing genotypes increasing with age [aOR 3.73, 95% CI (1.67–8.30) for patients 45–64 years of age]. Additionally, as compared to isolates with Beijing and other non-Beijing genotypes, significantly greater proportions of isolates with novel spoligotypes exhibited PTO- and PAS-resistance. Moreover, a markedly higher proportion of isolates with novel spoligotypes exhibited OFX-resistance as compared to isolates with other non-Beijing genotypes.

Conclusion

Our data demonstrated that the Beijing genotype is the predominant MTB sublineage in Fujian and that the prevalence rate of infection with this MTB genotype decreases with advancing patient age. Notably, the prevalence rate of this genotype in Fujian TB patients is relatively lower than in other regions of China. In addition, the emergence of novel spoligotypes of highly drug-resistant MTB isolates highlights the urgent need for ongoing molecular genotyping surveillance in Fujian.

Ethical Approval Statement

This project was approved by the Ethical Committee of the Fujian Province Center for Disease Control and Prevention (CDC). The written informed consent forms were obtained from the enrolled patients prior to study enrolment. Ethics have been respected in the whole period. The study was conducted in accordance with the Declaration of Helsinki.

Disclosure

The authors report no conflicts of interest in this work.

Additional information

Funding

This study was sponsored by the Construction of Fujian Provincial Scientific and Technological Innovation Platform (2019Y2001), Fujian provincial health technology project (2019-ZQN-28), the Beijing Hospitals Authority Ascent Plan (DFL20191601), and the Beijing Hospitals Authority Clinical Medicine Development of Special Funding (ZYLX202122). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.